JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.

INTERNATIONAL REVIEWS OF IMMUNOLOGY, published by Taylor & Francis Inc, is a leading academic journal that has been a cornerstone of immunological research since its inception in 1986. With an impressive impact factor and ranked in the top quartiles of its field (Q2 in both Immunology and Allergy), this journal offers a critical platform for the dissemination of influential findings and advancements within immunology. Spanning a diverse array of topics, from basic immune mechanisms to clinical applications, it aims to support the global scientific community in enhancing immunological understanding and therapeutic interventions. Researchers and professionals alike benefit from insights provided by renowned contributors, ensuring that the journal remains relevant in a rapidly evolving field. Directly accessible through subscription or institutional access, INTERNATIONAL REVIEWS OF IMMUNOLOGY is committed to fostering collaboration and innovation, making it an essential resource for anyone involved in immunological research and practice.

JOURNAL OF IMMUNOLOGICAL METHODS, published by Elsevier, is a prominent academic journal dedicated to advancing the field of immunology through innovative methodological research. With an ISSN of 0022-1759 and E-ISSN 1872-7905, this quarterly journal has maintained a steady publication rhythm since its inception in 1971 and looks forward to continued contributions until 2024. Positioned in the Q3 quartile for both Immunology and Allergy as well as Immunology, the journal ranks #150 out of 233 in Immunology and Allergy and #164 out of 236 in Immunology and Microbiology according to Scopus metrics, indicating active engagement within its field despite its developing status. The journal aims to provide a comprehensive platform for researchers and professionals to disseminate high-quality findings, collaborate on foundational methods, and tackle the pressing challenges within immunological research, fostering a deeper understanding of immune responses and promoting advancements in allergy treatments. While it operates under a subscription model, the scholarly contributions offered within these pages are invaluable for those aiming to stay at the forefront of immunological methodologies.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.